Singapore markets closed

Enzo Biochem, Inc. (ENZ)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
1.0500-0.0200 (-1.87%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.0700
Open1.0700
Bid1.0300 x 800
Ask1.0700 x 900
Day's range1.0400 - 1.0700
52-week range1.0400 - 2.7400
Volume114,913
Avg. volume109,219
Market cap53.787M
Beta (5Y monthly)0.71
PE ratio (TTM)N/A
EPS (TTM)-0.4700
Earnings date12 Jun 2024 - 17 Jun 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    Enzo Biochem (NYSE:ENZ) shareholders have endured a 69% loss from investing in the stock three years ago

    Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...

  • GlobeNewswire

    Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update

    FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's second-quarter revenue of $8.5 million improved year-over-year by 14%. During the 2024 period, we experienced a 25% revenue increase in the United States, driven by increased product demand in the drug development and cell and gene therapy mark

  • GlobeNewswire

    Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments

    FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Meeting Proposals Proposal One – The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri, M.D. to the Company’s Board of Directors to hold office for a term ending a